Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYH2072 in Healthy Participants
NCT07647783Phase 1Recruiting
- Sponsor
- InnovStone Therapeutics
- Start
- Jan 2026
- Primary completion
- Feb 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SYH2072 (3 arms), sponsored by InnovStone Therapeutics. Primary endpoints: Adverse Events at 8 months and Electrocardiogram at 8 months. Started Jan 2026; status: recruiting.
02
Drugs
SYH2072
Beyond the preview
Go deeper on NCT07647783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07647783.